Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889438 | 1.00 | LMNA (0.49) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4899806 | 0.97 | EGFR (0.50) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4488945 | 0.97 | EGFR (0.50) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4891620 | 0.93 | LMNA (0.57) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4498599 | 0.93 | LMNA (0.57) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4512306 | 0.88 | APOBEC3A (0.54) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4503995 | 0.88 | APOBEC3A (0.54) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4517907 | 0.87 | LMNA (0.55) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4898673 | 0.87 | LMNA (0.55) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL4900705 | 0.86 | ALDH1A1 (0.53) | LMNARAB9ASMN1; SMN2ALDH1A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-6855716-B2 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | AJINOMOTO CO., INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1318147-A1 | NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO. INC (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1193259-A1 | DIHYDROPYRIMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | CACNA1B, CACNA1D, CACNA1G | LMNA 1538/4885RAB9A 2075/4885SMN1; SMN2 350/4885 |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | LMNA 3830/4885RAB9A 1373/4885SMN1; SMN2 758/4885 |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | CACNA1I, CACNA1B, CACNA1E | LMNA 4114/4885RAB9A 1765/4885SMN1; SMN2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.